Valneva's chikungunya vaccine ixchiq® now authorized in canada for individuals aged 12 and older

Saint herblain (france), august 18, 2025 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that health canada has granted marketing authorization for its single-dose vaccine, ixchiq®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. this announcement adds to the adult marketing authorization already received in canada 1 and complements the adolescent label extension received in europe in april 20252.
VALN Ratings Summary
VALN Quant Ranking